Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advate PK comparison: one 3000 IU vial versus two 1500 IU vials in severe hemophilia A
2008-007347-13Phase 4Completed
- Sponsor
- Baxter International Inc.
- Start
- Jul 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of recombinant human coagulation factor VIII in hemophilia A (2 arms), sponsored by Baxter International Inc. Primary endpoint: Area under the plasma concentration versus time curve from 0 to 48 hours. Started Jul 2009; status: completed.
02
Drugs
recombinant human coagulation factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2008-007347-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007347-13.